Cantabio Pharmaceuticals, Inc.
Not enough financial coverage to compute a composite score for CTBO. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Companywww.cantabio.com
Cantabio Pharmaceuticals, Inc. , a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an Aß targeting small molecule pharmacological chaperone for use in the treatment of AD.
- CEO
- Gergely Toth
- IPO
- 2015
- Employees
- 15
- HQ
- Palo Alto, CA, US
Price Chart
Performance & Tape
- 52W High
- $1.01
- 52W Low
- $1.01
- 50D MA
- $1.01
- 200D MA
- $1.01
- Beta
- 0.12
- Avg Volume
- 10
Get TickerSpark's AI analysis on CTBO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CTBO Coverage
We haven't published any research on CTBO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CTBO Report →